지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.7
- 수록면
- 893 - 897 (5page)
- DOI
- 10.4143/crt.2024.015
이용수
초록· 키워드
오류제보하기
Purpose Bladder preservation chemoradiotherapy (CRT) in patients with a clinical complete response (cCR) following cisplatin-based neoadjuvant chemotherapy (NAC) is a promising treatment strategy for muscle-invasive bladder urothelial carcinoma (MIBC). A combined analysis of raw data from two prospective phase II studies was performed to better evaluate the feasibility of selective bladder preservation CRT.
Materials and Methods The analysis was based on primary efficacy data from two independent studies, including 76 MIBC patients receiving NAC followed by bladder preservation CRT. The efficacy data included metastasis-free survival (MFS) and disease-free survival (DFS). For the present analysis, starting point of survival was defined as the date of commencing CRT.
Results Among 76 patients, 66 had a cCR following NAC. Sixty-four patients received gemcitabine and cisplatin (GC) combination chemotherapy in neoadjuvant setting, and 12 received nivolumab plus GC. Bladder preservation CRT following NAC was generally well-tolerated, with low urinary tract symptoms being the most common late complication. With a median follow-up of 64 months, recurrence was recorded in 43 patients (57%): intravesical only (n=20), metastatic only (n=16), and both (n=7). In 27 patients with intravesical recurrence, transurethral resection, and Bacillus Calmette-Guerin treatment was given to 17 patients. Salvage cystectomy was performed in 10 patients. Median DFS was 46.3 (95% confidence interval [CI], 25.1 to 67.5) months, and the median MFS was not reached. Neither DFS nor MFS appeared to be affected by any of the baseline characteristics. However, DFS was significantly longer in patients with a cCR than in those without (hazard ratio, 0.465; 95% CI, 0.222 to 0.976).
Conclusion The strategy of NAC followed by selective bladder preservation CRT based on the cCR is feasible in the treatment of MIBC. A standardized definition of cCR is needed to better assess disease status post-NAC.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
Investigative and Clinical Urology
2022 .03
-
Neoadjuvant Nivolumab plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
Cancer Research and Treatment
2023 .04
-
Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study
Cancer Research and Treatment
2021 .10
-
Short-term outcomes of intravesical gemcitabine for non-muscle-invasive bladder cancer after recent approval for use in Korea
Investigative and Clinical Urology
2024 .09
-
Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer
Investigative and Clinical Urology
2020 .01
-
Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies
Investigative and Clinical Urology
2023 .05
-
Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Real-World, Retrospective Study
Cancer Research and Treatment
2024 .07
-
Risk factors for failing to complete gemcitabine–cisplatin neoadjuvant chemotherapy in muscle invasive bladder cancer patients
Investigative and Clinical Urology
2024 .05
-
Results of Intravesical Chemo-Hyperthermia in High-risk Non-muscle Invasive Bladder Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Toward Better Predictions of Chemosensitivity: Comparative Study of Conventional and Simulated Chemosensitivity Tests for Bladder Cancer Cell Lines
Annals of Laboratory Medicine
2017 .07
-
Diabetes is an Important Risk Factor for Metastasis in Non-Muscle-Invasive Bladder Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Concurrent chemoradiotherapy improves survival outcome in muscle-invasive bladder cancer
Radiation oncology journal : ROJ
2015 .01
-
Seminal Vesicle Involvement by Carcinoma In Situ of the Bladder: Clonal Analysis Using Next-Generation Sequencing to Elucidate the Mechanism of Tumor Spread
Cancer Research and Treatment
2020 .01
-
Trends in the Use of Chemotherapy before and after Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer in Korea
Journal of Korean Medical Science
2015 .01
-
Clinicopathological Characteristics of Urinary Bladder Tumors in Korean Patients 20 Years or Younger
Journal of Korean Medical Science
2018 .01
-
Gender-related outcomes in robot-assisted radical cystectomy: A multi-institutional study
Investigative and Clinical Urology
2022 .01
-
Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review
Investigative and Clinical Urology
2020 .01
-
Previous Bladder Cancer History in Patients with High-Risk, Non–muscle-invasive Bladder Cancer Correlates with Recurrence and Progression: Implications of Natural History
Cancer Research and Treatment
2015 .01
-
Single Early Intravesical Instillation of Epirubicin for Preventing Bladder Recurrence After Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma
Cancer Research and Treatment
2024 .07
-
Implantable Bladder Sensors: A Methodological Review
International Neurourology Journal
2015 .01
최근 본 자료
댓글(0)
0